These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34034491)

  • 1. The Use of Dalbavancin with a Dermal Substitute Application - a Case Report.
    B L; M H; P LB; M H
    Acta Chir Plast; 2021; 63(1):14-17. PubMed ID: 34034491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
    Petrakis V; Panagopoulos P; Papanas N
    Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller : Proposal for novel treatment indications.
    Mischlinger J; Lagler H; Harrison N; Ramharter M
    Wien Klin Wochenschr; 2017 Sep; 129(17-18):642-645. PubMed ID: 28776100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of clinical evidence for dalbavancin].
    Rodríguez-Pardo D
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
    Cardona AF; Wilson SE
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer treatment options for skin and soft tissue infections.
    Raghavan M; Linden PK
    Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
    Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
    Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of dalbavancin against gram-positive cocci isolated from skin and soft tissue infections in Poland.
    Stefaniuk EM; Dudek M; Hryniewicz W
    Diagn Microbiol Infect Dis; 2019 Dec; 95(4):114881. PubMed ID: 31477408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin use in an academic medical centre and associated cost savings.
    Streifel AC; Sikka MK; Bowen CD; Lewis JS
    Int J Antimicrob Agents; 2019 Nov; 54(5):652-654. PubMed ID: 31398481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.